FDA awards $35m to improve US drug production

By Nick Taylor

- Last updated on GMT

Related tags Pharmacology Pharmaceutical drug

The FDA has awarded a $35m (€26m) grant to make US drug production less expensive and reverse the offshoring trend.

Over the next five years the National Institute for Pharmaceutical Technology and Education (NIPTE) will receive up to $35m from the US Food and Drug Administration (FDA) to improve manufacturing. By increasing the efficiency of drug production NIPTE hopes to make the US more competitive.

Development and manufacturing costs can be reduced, quality of our drugs can be improved, and outsourcing trends can be reversed by developing science-based standards for drug development and manufacturing​”, Prabir Basu, executive director of NIPTE, said.

Goals of the project include promotion of continuous manufacturing and improvement of small batch production. Making gains in these and other areas could encourage US biopharm to invest in local, in-house capacity by reducing cost and energy use while cutting time to market.

Basu said: “Outsourcing of drugs and drug intermediates are increasing at an alarming rate, potentially threatening overall quality of our drugs accompanied by huge job losses in this country​.”

Regaining the edge

Increasing innovation and efficiency is often cited​ as a way for the US to regain an edge over low-cost manufacturing regions and some have called for governmental support to stimulate improvements.

Governments at all levels should make investments in infrastructure and facilitate its expansion to encourage research and development, production and academic clustering​”, a 2010 National Association of Manufacturers report​ said.

The FDA has supported innovation with grants to improve biopharm production​ and understanding of nanoparticles​. NIPTE and the FDA worked together to make an excipient information website before trying to improve US biopharm production.

Progress in this area will mean safer, more efficient, and less costly drug production here in the US, and we are looking forward to NIPTE's findings​”, Helen Winkle, director, FDA Office of Pharmaceutical Sciences, said.

Related news

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us


View more